ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma | University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD | Reach Grants | 2017 | North Carolina |
Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies | The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD | Reach Grants | 2018 | Maryland |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma | Children’s Hospital of Philadelphia / John Maris, MD | Reach Grants | 2016 | Pennsylvania |
Targeting PLK1 as a Common Mechanism in Ph-like ALL | University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD | Reach Grants | 2016 | Texas |
Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor | Baylor College of Medicine / William Decker, PhD | Reach Grants | 2013 | Texas |
Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors | Dana-Farber Cancer Institute / Loren Walensky, MD/PhD | Reach Grants | 2021 | Massachusetts |
B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers | University of Texas Southwestern Medical Center / James Amatruda, MD, PhD | Reach Grants | 2013 | Texas |
Optimizing TCRαβ+/CD19+-depleted haploidentical HSCT for ALL using donor-derived genome-edited CAR T cells | Stanford University School of Medicine / Alice Bertaina, MD/PhD | Reach Grants | 2019 | California |
Enhancing TKI Therapy in Ph-Like Leukemia | The Regents of the University of California, Irvine / David Fruman, PhD | Reach Grants | 2022 | California |
Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL | University of Colorado Denver / Doug Graham, MD, PhD | Reach Grants | 2013 | Colorado |